

electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB

Written comments and/or suggestions regarding the items contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Charles MacKay, Ph.D., NIH Project Clearance Officer, Division of Grants Policy, Office of Policy for Extramural Research Administration, OER, NIH, Rockledge II, Rm. 2196, 6701 Rockledge Dr., Bethesda, MD 20892-7730, or call non-toll free at (301) 435-0978 or E-mail your request, including your address to: mackay@odrockm1.od.nih.gov.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before August 10, 1998.

Dated: June 30, 1998.

Diana Jaeger,

Director, Division of Grants Policy, Office of Policy for Extramural Research Administration, OER, NIH.

[FR Doc. 98-18321 Filed 7-9-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Clinical Trials Musculoskeletal.

Date: August 3, 1998.

Time: 10:00 a.m. to 1:00 p.m.

Place: To review and evaluate grant applications.

Place: Natcher Bldg., 45 Center Drive, Room 5AS25N, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: John R. Lymangrover, Scientific Review Administrator, NIAMS, 45 Center Drive, Room 5AS 25, Bethesda, MD 20892-650, (301) 594-4952.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Osteoporosis Center.

Date: August 10, 1998.

Time: 10 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: Natcher Bldg., 45 Center Drive, Room 5AS25N, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: John R. Lymangrover, Scientific Review Administrator, NIAMS, 45 Center Drive, Room 5AS 25, Bethesda, MD 20892-650, (301) 594-4952.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: July 2, 1998.

LaVeen Ponds,

Acting Committee Management Officer, NIH.

[FR Doc. 98-18317 Filed 7-9-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel National Research Service Award.

Date: July 17, 1998.

Time: 9:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Bruce K. Wetzel, Scientific Review Administrator, Office of Scientific Review, NIGMS, Natcher Building, Room 1AS-19, Bethesda, MD 20892, (301) 594-3907.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: July 2, 1998.

LaVeen Ponds,

Acting Committee Management Officer, NIH.

[FR Doc. 98-18318 Filed 7-9-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Notice of International Workshop to "Evaluate Research Needs on the Use and Safety of Medicinal Herbs"

The Workshop will be held at the National Institute of Environmental Health Sciences, Conference Facility in Research Triangle Park, North Carolina September 23 and 24 1998 from 8:30 to 5:00 each day.

Background

Herbal medicines and dietary supplements account for one of the fastest growing markets in U.S. pharmacies and constitute a multi-billion dollar industry. It is estimated that as many as 1,500 botanicals are sold in the U.S. as dietary supplements or ethnic traditional medicines. It is further estimated that greater than 50% of the U.S. population uses one or more dietary supplements including medicinal herbs. Medicinal herbs are not, however, subject to the same testing for efficacy or safety mandated for prescription or over-the-counter drugs. Given the increasing use of some medicinal herbs and the paucity of toxicological data, this workshop will bring together a panel of national and international experts to discuss the use of the medicinal herbs and dietary supplements and to establish research needs that address public health